Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Nkarta expects to provide an update on first patient dosing for NKX019 in LN in the first half of 2024.
- Nkarta expects to provide an update on first patient dosing for NKX019 in LN in the first half of 2024.
- In March 2024, Nkarta completed an underwritten offering of common stock and pre-funded warrants with gross proceeds of $240.1 million.
- Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of $450.0 million as of March 31, 2024.
- Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024.